RxDoctor Payments Data

Jared Kvapil, MD

Cardiovascular Disease · Kansas City, KSNPI 1972814663

Payments from drug & device makers

$3,405in general payments, 2019–2025

Across 117 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Boston Scientific$660
  • Abbott$505
  • Amgen$221
  • Edwards Lifesciences$128
  • Pfizer$118
  • plus $641 from 15 others

What the payments were for

  • Food & beverage$3,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,405 in reported general payments places this provider in the 55th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$96,771
Medicare patients
690
Services billed
1,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten22$168,580
EliquisApixaban124$145,643
Repatha SureclickEvolocumab160$106,438
XareltoRivaroxaban32$44,216
FarxigaDapagliflozin Propanediol24$23,781
EntrestoSacubitril/Valsartan16$21,106
JardianceEmpagliflozin22$20,265
Praluent PenAlirocumab38$18,773
Atorvastatin Calcium357$4,971
Ezetimibe124$3,121
Rosuvastatin Calcium189$2,360
Carvedilol221$2,126
Metoprolol Succinate151$1,876
Enoxaparin Sodium12$1,314
Bumetanide22$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$1,132$168,58022 claims
PfizerEliquis$118$145,643124 claims
Johnson & JohnsonXarelto$12$44,21632 claims
AstraZenecaFarxiga$34$23,78124 claims
Boehringer IngelheimJardiance$18$20,26522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →